FDA Approves Afrezza for Pediatric Use, Fulfilling Final Postmarketing Requirement
Summary
MannKind announced FDA approval for its Afrezza insulin inhalation powder for pediatric use, which also fulfills the final postmarketing requirement for the drug.
Key Events
-
FDA Approval for Pediatric Use
The U.S. Food and Drug Administration (FDA) approved Afrezza (insulin human) Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes.
-
Expanded Market Opportunity
This approval opens a new market segment, as more than 350,000 children and adolescents in the United States are living with diabetes, the majority requiring lifelong insulin therapy.
-
Final Postmarketing Requirement Met
The supplemental biologics license application for the pediatric indication has fulfilled the last remaining postmarketing requirement for Afrezza, removing a significant regulatory overhang.
Analysis
This FDA approval significantly expands the addressable market for Afrezza to include children and adolescents aged 6 and older with type 1 and type 2 diabetes, a population exceeding 350,000. Crucially, this approval also satisfies the last remaining postmarketing requirement for Afrezza, removing a significant regulatory burden and associated costs for MannKind.
At the time of this filing, MNKD was trading at $3.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.23 to $6.51. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.